Mutant KRAS at the Heart of Tumor Immune Evasion
Abstract
No abstract availableKeywords
Funding Information
- Wellcome Trust
- European Research Council
- Cancer Research UK
- Medical Research Council
This publication has 7 references indexed in Scilit:
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityNature, 2019
- Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancerScience Translational Medicine, 2019
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaNature Medicine, 2019
- Progress in targeting RAS with small molecule drugsBiochemical Journal, 2019
- Kras and Tumor Immunity: Friend or Foe?Cold Spring Harbor Perspectives in Medicine, 2017
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung CancerJAMA, 2017
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsNature, 2013